REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Body Recomp Stack

Fat Lossintermediate

86

synergy

86
Peptides

3

Avg Daily mcg

1,100

Level

intermediate

Added

May 17, 2026

Overview

The Body Recomp Stack is designed for simultaneous muscle building and fat reduction — the "have it all" protocol that combines GH axis optimization with recovery support. It pairs the proven CJC-1295 + Ipamorelin GH stack with BPC-157 to support the connective tissue, joints, and recovery that intensive body recomposition training demands. CJC-1295 and Ipamorelin drive the anabolic and lipolytic effects of elevated GH — increased protein synthesis, improved fat metabolism, better sleep quality, and enhanced recovery capacity. The GH axis improvements are particularly powerful for body recomposition because GH drives lipolysis (fat breakdown for energy) while also supporting lean tissue preservation and growth. BPC-157 addresses the structural demands of the training required for recomposition. Heavy lifting and high-volume training place significant stress on tendons, ligaments, and joints — the connective tissue structures that most often limit training consistency. BPC-157''s localized healing effects keep these structures healthy during progressive overload, allowing users to train harder and more consistently without injury interruptions. The practical outcome: GH optimization drives the hormonal environment for simultaneous fat loss and muscle gain, while BPC-157 keeps the body structurally sound enough to train at the intensities required to achieve that environment. Many athletes and clinicians consider this the most complete body composition protocol available without exogenous hormones.

Dosing Protocol

CJC-1295

Every day· subcutaneous

300 mcg

per dose

Ipamorelin

Every day· subcutaneous

300 mcg

per dose

BPC-157

Twice per day· subcutaneous

250 mcg

per dose

Goals & Evidence

Simultaneous fat loss and muscle gainTraining recoveryBody compositionJoint health
Evidence tier:Animal Studies

Warnings

  • BPC-157 is currently FDA Category 2 — reclassification to Category 1 pending May 2026.

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.